Literature DB >> 31912565

Primary cutaneous γδ T-cell lymphoma with unusual immunophenotype: A case report and review of published work.

Hiroaki Kamijo1, Tomomitsu Miyagaki1,2, Yurie Norimatsu1, Kentaro Awaji1, Tomonori Oka1, Hiraku Suga1, Makoto Sugaya1,3, Shinichi Sato1.   

Abstract

Primary cutaneous γδ T-cell lymphoma (CGD-TCL) is a rare form of primary cutaneous lymphoma. The histopathological features of CGD-TCL are still unclear because of its rarity. Here, we report a case of a 77-year-old Japanese man who presented with a 9-month history of erythematous plaques on his left forearm. Skin biopsy specimens revealed the infiltration of atypical medium/large-sized lymphocytes from the epidermis to the deep dermis. Atypical lymphocytes were positive for CD3, CD5, CD8 and Vδ1, and negative for CD4, CD7, CD56, EBER-ISH, intracellular antigen-1, granzyme B and perforin. CD30 was partially expressed. We also reviewed 246 cases of CGD-TCL from the published work. CD4- CD8- double-negative cases were 113 of 196 cases (57.6%), followed by CD4- CD8+ cases (52/196, 26.5%). CD5 was expressed in 25.8% of the cases (34/132). At least one cytotoxic molecule marker was expressed in 150 of 160 cases (93.8%). Some cases showed an indolent clinical course, especially in mycosis fungoides-like CGD-TCL cases. CD5 positivity and lack of cytotoxic molecule expression could be associated with a better prognosis. In addition, CD30 expression was found in approximately half of CGD-TCL cases (51/112 cases), suggesting that brentuximab vedotin could be a good treatment option for such patients. Further studies with more cases with detailed clinical and pathological information are necessary to elucidate the etiology and prognostic markers of this entity.
© 2020 Japanese Dermatological Association.

Entities:  

Keywords:  CD30; CD5; CD8; cytotoxic molecules; primary cutaneous γδ T-cell lymphoma

Mesh:

Substances:

Year:  2020        PMID: 31912565     DOI: 10.1111/1346-8138.15215

Source DB:  PubMed          Journal:  J Dermatol        ISSN: 0385-2407            Impact factor:   4.005


  1 in total

1.  Successful salvage therapy for refractory primary cutaneous gamma-delta T-cell lymphoma with a combination of brentuximab vedotin and gemcitabine.

Authors:  Sophie Voruz; Laurence de Leval; Anne Cairoli
Journal:  Exp Hematol Oncol       Date:  2021-05-13
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.